Shares of the direct-to-consumer telehealth company Hims & Hers have been halved over the past six months, trading near $27. Investors are now weighing whether the steep sell-off presents a buying opportunity or signals deeper troubles ahead.
While the healthcare sector has surged 17.4% in six months, outpacing the S&P 500, regulatory headwinds and valuation concerns demand a selective approach. We examine one stock with a durable edge and two facing significant challenges.
Analysts have pinned high hopes on several names, but a closer look reveals a more nuanced picture. We examine one company likely to justify the optimism and two where significant risks may be overshadowing the bullish price targets.
Morgan Stanley and Evercore ISI reaffirm bullish ratings on iRhythm, citing strong Q4 preliminary results and growth potential from its next-gen cardiac monitoring technology.
